The potentially avoidable death counts in the last column (in red) are beyond alarming. The results in the next to last column (in green) resemble the expected deaths in a normal seasonal flu year. Obviously, the skeptics will reject this result by saying that there are many other factors that would have ruled out this overly optimistic result. Examples include questioning the accuracy of India’s data, the difference in average ages of each country’s population (India has far more young people), and the lack of domestic manufacturing and supply chain resources to produce and distribute the needed drugs.

After nearly a year-and-a-half and over 618,000 recorded COVID-related deaths in the U.S. alone, the FDA has finally released an emergency use authorization for REGEN-COV, a new drug that was being tested in 2020 (pre-Biden). Primary care physicians can now use it as an early treatment option. Before now, the only authorized COVID-19 early treatment my family doctor had, per the July 2021 update to NIH guidelines, was to recommend quarantine and then wait until symptoms go away or report to a hospital if they get worse. Of note, these updated guidelines continue to identify hydroxychloroquine (HCQ) as a prohibited drug – although this should not be a surprise considering the war on HCQ began soon after President Trump dared to recommend it.